keyword
MENU ▼
Read by QxMD icon Read
search

Tamoxifen aromatase

keyword
https://www.readbyqxmd.com/read/29274928/optimal-adjuvant-endocrine-treatment-of-er-her2-breast-cancer-patients-by-age-at-diagnosis-a-population-based-cohort-study
#1
G M H E Dackus, K Jóźwiak, G S Sonke, E van der Wall, P J van Diest, M Hauptmann, S Siesling, S C Linn
BACKGROUND: Prior randomised controlled trials on adjuvant hormonal therapy included HER2any patients; however, a differential effect of aromatase inhibitors (AIs) versus tamoxifen (TAM) may have been missed in ER+/HER2+ patients that comprise 7-15% of all breast cancer patients. In addition, a woman's hormonal microenvironment may influence sensitivity to TAM and AIs in the adjuvant setting, which changes during menopausal transition, a process that takes years. We studied the efficacy of AIs versus TAM in ER+/HER2+ breast cancer patients grouped by age at diagnosis as a proxy for menopausal status using treatment and outcome data from the nationwide population-based Netherlands Cancer Registry (NCR)...
December 21, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29251675/hormone-receptor-positive-breast-cancer-state-of-the-art
#2
Parvin F Peddi
PURPOSE OF REVIEW: Hormone receptor (HR) positive breast cancer represents the vast majority of breast cancer cases. Treatment for these patients has been 5 years of endocrine therapy in the localized setting and endocrine therapy alone in the metastatic setting until progression of disease and switch to chemotherapy until quite recently. RECENT FINDINGS: The current article will review recent data on role of extended endocrine therapy with tamoxifen and aromatase inhibitors and adjuvant bisphosphonates in the localized disease setting...
February 2018: Current Opinion in Obstetrics & Gynecology
https://www.readbyqxmd.com/read/29243101/fractures-in-a-nationwide-population-based-cohort-of-users-of-breast-cancer-hormonal-therapy
#3
Joan M Neuner, Yushu Shi, Amanda L Kong, Sailaja Kamaraju, Elizabeth C Smith, Alicia J Smallwood, Purushottam W Laud, John A Charlson
PURPOSE: Although users of aromatase inhibitors have higher total fracture risk in some randomized trials, little is known about their risk outside of clinical trials or in older higher-risk cohorts. METHODS: In a population-based retrospective cohort study, we identified all older US Medicare D prescription drug insurance plan-enrolled women who had initial breast cancer surgery in 2006-2008 and began hormonal therapy (an aromatase inhibitor (AI) or tamoxifen) within the subsequent year...
December 15, 2017: Journal of Cancer Survivorship: Research and Practice
https://www.readbyqxmd.com/read/29234250/are-we-ready-to-use-esr1-mutations-in-clinical-practice
#4
REVIEW
Rinath Jeselsohn
The recurrent ligand-binding domain ESR1 mutations are an important mechanism of endocrine resistance in estrogen receptor-positive (ER+) metastatic breast cancer. These mutations evolve under the selective pressure of endocrine treatments and are rarely found in treatment-naïve ER+ breast cancers. Preclinical studies showed that these mutations lead to ligand-independent activity facilitating resistance to aromatase inhibitors and relative resistance to tamoxifen and fulvestrant. Retrospective analyses of ESR1 mutations in baseline plasma circulating tumor DNA from clinical trials suggest that these mutations are prognostic of poor overall survival and predictive of resistance to aromatase inhibitors in metastatic disease...
October 2017: Breast Care
https://www.readbyqxmd.com/read/29230660/dietary-intake-of-soy-and-cruciferous-vegetables-and-treatment-related-symptoms-in-chinese-american-and-non-hispanic-white-breast-cancer-survivors
#5
Sarah J O Nomura, Yi-Ting Hwang, Scarlett Lin Gomez, Teresa T Fung, Shu-Lan Yeh, Chiranjeev Dash, Laura Allen, Serena Philips, Leena Hilakivi-Clarke, Yun-Ling Zheng, Judy Huei-Yu Wang
PURPOSE: This project was undertaken to examine the association between dietary intake of soy or cruciferous vegetables and breast cancer treatment-related symptoms among Chinese-American (CA) and Non-Hispanic White (NHW) breast cancer survivors. METHODS: This cross-sectional study included 192 CA and 173 NHW female breast cancer survivors (stages 0-III, diagnosed between 2006 and 2012) recruited from two California cancer registries, who had completed primary treatment...
December 11, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29230126/endocrine-therapy-for-early-breast-cancer-updated-review
#6
REVIEW
Alexander Tremont, Jonathan Lu, John T Cole
Background: Although breast cancer is still the second most common cause of cancer-related deaths, breast cancer mortality has been declining because of advances in the use of adjuvant therapies. Methods: We summarize clinical trials involving endocrine therapies used to treat early breast cancer and discuss their inception and recent advances. Results: Endocrine therapies such as tamoxifen have revolutionized the treatment of breast cancer, resulting in significant decreases in cancer-related mortality...
2017: Ochsner Journal
https://www.readbyqxmd.com/read/29223989/geographic-variation-of-adjuvant-breast-cancer-therapy-initiation-in-the-united-states-lessons-from-medicare-part-d
#7
John A Charlson, Emily L McGinley, Ann B Nattinger, Joan M Neuner, Liliana E Pezzin
Background: Drug utilization under Medicare Part D varies significantly by geographic region. This study examined the extent to which geographic variation in Part D plan characteristics contributes to the variation in choice of initial endocrine therapy agent among women with incident breast cancer. Methods: Two-stage multivariate regression analyses were applied to the 16,541 women identified from Medicare claims as having incident breast cancer in 2006-2007. The first stage determined the effect of state of residence on the probability of having an aromatase inhibitor (AI), as opposed to tamoxifen, as initial endocrine therapy...
December 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29205077/forty-years-of-landmark-trials-undertaken-by-the-danish-breast-cancer-cooperative-group-dbcg-nationwide-or-in-international-collaboration
#8
Bent Ejlertsen, Birgitte Vrou Offersen, Jens Overgaard, Peer Christiansen, Maj-Britt Jensen, Niels Kroman, Ann Søgaard Knoop, Henning Mouridsen
BACKGROUND: Over the past 40 years the Danish Breast Cancer Cooperative Group (DBCG) has made significant contributions to improve outcome and to make treatment of patients with early breast cancer more tolerable through nationwide and international trials evaluating loco-regional and systemic treatments. These trials have been instrumental to establish standards for the treatment of early breast cancer. METHODS: The DBCG 82 trials had a global impact by documenting that the significant gain in loco-regional recurrence from postmastectomy radiation added to systemic therapy was associated with a reduction in distant recurrence and mortality in high-risk pre- and postmenopausal patients...
December 5, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/29202611/aurora-kinase-a-as-a-possible-marker-for-endocrine-resistance-in-early-estrogen-receptor-positive-breast-cancer
#9
Anne E Lykkesfeldt, Benedikte R Iversen, Maj-Britt Jensen, Bent Ejlertsen, Anita Giobbie-Hurder, Birgit E Reiter, Tove Kirkegaard, Birgitte B Rasmussen
BACKGROUND: Cell culture studies have disclosed that the mitotic Aurora kinase A is causally involved in both tamoxifen and aromatase inhibitor resistant cell growth and thus may be a potential new marker for endocrine resistance in the clinical setting. MATERIAL AND METHODS: Archival tumor tissue was available from 1323 Danish patients with estrogen receptor (ER) positive primary breast cancer, who participated in the Breast International Group (BIG) 1-98 trial, comparing treatment with tamoxifen and letrozole and both in a sequence...
December 4, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/29187460/adjuvant-breast-cancer-treatments-induce-changes-in-homoarginine-level-a-prospective-observational-study
#10
Hanna Aula, Tanja Skyttä, Suvi Tuohinen, Tiina Luukkaala, Mari Hämäläinen, Vesa Virtanen, Pekka Raatikainen, Eeva Moilanen, Pirkko-Liisa Kellokumpu-Lehtinen
AIM: To identify patients with breast cancer at risk for cardiotoxicity, we evaluated homoarginine (HA) behavior during adjuvant treatment. PATIENTS AND METHODS: Eighty-one patients received radiotherapy (RT) with or without endocrine treatment, and 19 received chemotherapy, RT and endocrine therapy. Serum HA, asymmetric dimethylarginine (ADMA) and high-sensitivity cardiac troponin T (hscTnT) were measured and echocardiography was performed before chemotherapy, and before and after RT...
December 2017: Anticancer Research
https://www.readbyqxmd.com/read/29177573/triptorelin-a-review-of-its-use-as-an-adjuvant-anticancer-therapy-in-early-breast-cancer
#11
James E Frampton
A 1-month formulation of the gonadotrophin-releasing hormone agonist (GnRHa) triptorelin (Decapeptyl®) has been approved in the EU as an adjuvant treatment in combination with tamoxifen or an aromatase inhibitor (AI), of endocrine-responsive, early-stage breast cancer in women at high risk of recurrence who are confirmed as premenopausal after completion of chemotherapy. This indication reflects the results of the 5-year SOFT and TEXT studies, especially SOFT, in which ovarian function suppression (OFS; mainly achieved with triptorelin) added to tamoxifen provided a significant benefit in the overall study population of premenopausal patients only after adjusting for prognostic factors...
December 2017: Drugs
https://www.readbyqxmd.com/read/29168668/the-occurrence-of-fractures-after-adjuvant-treatment-of-breast-cancer-a-dbcg-register-study
#12
Bent Kristensen, Bent Ejlertsen, Maj-Britt Jensen, Henning T Mouridsen
BACKGROUND: Adjuvant treatment in breast cancer patients especially with aromatase inhibitors (AIs) has adverse effects on bone metabolism resulting in an increased occurrence of fractures. In order to demonstrate this occurrence, long-term follow-up studies are necessary. From several national registries in Denmark, it is possible to link data from different sources and analyze this issue. METHODS: A study cohort of 68,842 breast cancer patients prospectively diagnosed and registered in the Danish Breast Cancer Cooperative Group's database during the period 1995-2012 formed the basis of the analysis...
November 23, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/29164377/systemic-and-local-effects-of-vaginal-dehydroepiandrosterone-dhea-ncctg-n10c1-alliance
#13
Debra L Barton, Lynne T Shuster, Travis Dockter, Pamela J Atherton, Jacqueline Thielen, Stephen N Birrell, Richa Sood, Patricia Griffin, Shelby A Terstriep, Bassam Mattar, Jacqueline M Lafky, Charles L Loprinzi
BACKGROUND: Dehydroepiandrosterone (DHEA) is helpful for treating vaginal symptoms. This secondary analysis evaluated the impact of vaginal DHEA on hormone concentrations, bone turnover, and vaginal cytology in women with a cancer history. METHODS: Postmenopausal women, diagnosed with breast or gynecologic cancer, were eligible if they reported at least moderate vaginal symptoms. Participants could be on tamoxifen or aromatase inhibitors (AIs). Women were randomized to 3...
November 21, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29155450/risk-of-ovarian-function-recovery-should-be-considered-when-switching-from-treatment-with-adjuvant-tamoxifen-to-aromatase-inhibitor-therapy-in-women-with-chemotherapy-induced-amenorrhea
#14
https://www.readbyqxmd.com/read/29135127/is-switching-to-tamoxifen-the-only-choice-of-treatment-for-improving-aromatase-inhibitor-toxicity
#15
Kadri Altundag
No abstract text is available yet for this article.
September 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29131988/treatment-adoption-and-relative-effectiveness-of-aromatase-inhibitors-compared-to-tamoxifen-in-early-breast-cancer-a-multi-institutional-observational-study
#16
Arlindo R Ferreira, Ana Palha, Lurdes Correia, Pedro Filipe, Vasco Rodrigues, Ana Miranda, Rosário André, João Fernandes, Joaquim Gouveia, José L Passos-Coelho, António Moreira, Margarida Brito, Joana Ribeiro, Otto Metzger-Filho, Nancy U Lin, Luís Costa, Inês Vaz-Luis
BACKGROUND: Since 2005, aromatase inhibitors (AIs) have been the adjuvant treatment of choice for postmenopausal women with early breast cancer (BC). In this study we characterize the adoption of AIs in Portugal, variables associated with treatment administration, and compare its effectiveness (either in monotherapy or sequential therapy) to tamoxifen monotherapy (TAM). PATIENTS AND METHODS: This was a retrospective cohort study that included postmenopausal women with stage I-III hormone receptor (HR) positive BC diagnosed from 2006 to 2008 and treated with adjuvant endocrine therapy in four participating institutions...
November 10, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29103853/adherence-to-adjuvant-endocrine-therapy-in-christchurch-women-with-early-breast-cancer
#17
B Robinson, B Dijkstra, V Davey, S Tomlinson, C Frampton
AIMS: To assess adherence to adjuvant endocrine therapy by a real-world cohort of women in Christchurch and to determine any associated factors. MATERIALS AND METHODS: Records were retrieved of all women newly diagnosed with early breast cancer and registered on the Christchurch Breast Cancer Patient Register over 4 years from June 2009. Demographic and pathological factors, dates of starting and stopping endocrine therapies and reported side-effects were collected...
November 2, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/29100043/treatment-landscape-of-advanced-breast-cancer-patients-with-hormone-receptor-positive-her2-negative-tumors-data-from-the-german-praegnant-breast-cancer-registry
#18
Andreas D Hartkopf, Jens Huober, Bernhard Volz, Naiba Nabieva, Florin-Andrei Taran, Judith Schwitulla, Friedrich Overkamp, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Michael P Lux, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W Beckmann, Erik Belleville, Pauline Wimberger, Carsten Hielscher, Matthias Geberth, Nikos Fersis, Wolfgang Abenhardt, Christian Kurbacher, Rachel Wuerstlein, Christoph Thomssen, Michael Untch, Peter A Fasching, Wolfgang Janni, Tanja N Fehm, Diethelm Wallwiener, Sara Y Brucker, Andreas Schneeweiss
PURPOSE: This study describes comprehensive data from a breast cancer registry concerning the use of endocrine treatment (ET) and chemotherapy in the first, second and higher therapy lines in hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC). METHODS: The PRAEGNANT study is a real-time registry for patients with MBC. Therapies were categorized into the following categories: chemotherapy, aromatase inhibitor (AI), tamoxifen, fulvestrant, or everolimus plus ET and reported for first, second and third line or higher therapy use...
October 26, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29098396/survival-benefit-of-tamoxifen-and-aromatase-inhibitor-in-male-and-female-breast-cancer
#19
Holm Eggemann, Udo Altmann, Serban-Dan Costa, Atanas Ignatov
BACKGROUND: Our goal was to compare the survival advantage of tamoxifen (TAM) and aromatase inhibitor (AI) in female (FBC) and male breast cancer (MBC). PATIENTS AND METHODS: We performed a retrospective study of 2785 FBC and 257 MBC patients treated with hormonal therapy. RESULTS: The median follow-up was 106 months (range 3-151 months) and 42 months (range 2-115 months) for FBC and MBC, respectively. The patients were divided into two groups according to the hormonal therapy used: TAM-treated and AI-treated...
November 2, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29071118/influence-of-aromatase-inhibitors-therapy-on-the-occurrence-of-rheumatoid-arthritis-in-women-with-breast-cancer-results-from-a-large-population-based-study-of-the-italian-society-for-rheumatology
#20
Marta Caprioli, Greta Carrara, Garifallia Sakellariou, Ettore Silvagni, Carlo Alberto Scirè
OBJECTIVES: The purpose of this study was to evaluate the risk of developing rheumatoid arthritis (RA) in a population of patients with breast cancer treated with aromatase inhibitors (AIs) compared with tamoxifen. METHODS: Data were collected from the administrative healthcare database of Lombardy Region, Italy, from 2004 to 2013. This study follows a nested cohort design, including women with a diagnosis of breast cancer starting treatment with tamoxifen, anastrozole, exemestane or letrozole...
2017: RMD Open
keyword
keyword
30009
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"